FGL2 and central nervous system cancer: Our previously published data showed that overexpression of FGL2 correlates with upregulated expression of negative immune checkpoints, decreased granulocyte–macrophage colony-stimulating factor–induced CD103+ DC differentiation, faster glioma progression, and poor clinical outcomes in brain malignancies20–23.